Fibroelastose endocárdica
Revisado por Dr Krishna Vakharia, MRCGPÚltima atualização por Dr Colin Tidy, MRCGPLast updated 21 Set 2023
Atende aos diretrizes editoriais
- BaixarBaixar
- Compartilhar
- Language
- Discussão
- Versão em Áudio
- Add to preferred sources on Google
Profissionais de Saúde
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our artigos de saúde more useful.
Neste artigo:
Continue lendo abaixo
What is endocardial fibroelastosis?1
Endocardial fibroelastosis was first described by Weinberg and Himmelfarb in 1943 as a thick subendocardial layer of connective tissue and elastin, encapsulating the underlying myocardium of the left atrium and left ventricle.
The primary form, which is not associated with any significant structural anomaly of the heart, is rare, but endocardial fibroelastosis is still a major feature of several congenital heart diseases, most notably lesions with left heart obstructions including hypoplastic left heart syndrome.2
Patogênese
Voltar ao conteúdoThe disease can be primary or secondary, although some argue it is only ever secondary.3
The two forms of primary endocardial fibroelastosis (EFE) are dilated (most common), and contracted.4 It has been suggested that one form may progress to the other.
Primary dilated EFE occurs when the heart is otherwise normal and there is no other cause of unexplained heart failure.
Secondary dilated EFE is associated with estenose aórtica or atresia.
Secondary contracted EFE is associated with hypoplastic left heart syndrome.
Continue lendo abaixo
Endocardial fibroelastosis epidemiology4
Voltar ao conteúdoPrimary endocardial fibroelastosis is rare - only 1-2% of all congenital heart diseases. The number of cases has fallen dramatically in recent years, possibly secondary to better antenatal scanning.
It may be familial (10%) with a predominantly X-linked pattern.
It affects both sexes equally, usually presenting during the first 3-6 months of life in 80% of cases.
Typical age of diagnosis is 2-12 months. It rarely is reported in adolescents and adults.
It is an important cause of non-immune hidropisia fetal.5
What causes endocardial fibroelastosis? (Aetiology)1
Voltar ao conteúdoThe presence of endocardial fibroelastosis has been reported in several other cardiac diseases such as:
Cardiomyopathies.
Viral myocarditis.
Lysosomal storage diseases.
Congenital heart diseases such as aortic stenosis, coarctation of the aorta, or hypoplastic left heart syndrome.
The macroscopic and microscopic appearance led to the uniform diagnosis of endocardial fibroelastosis.
Continue lendo abaixo
Endocardial fibroelastosis symptoms (presentation)
Voltar ao conteúdoIt typically presents with typical signs of congestive heart failure (CHF) in previously healthy children less than 6 months old.6
Sintomas
Falta de ar.
Tosse.
Chiado.
Feeding difficulty.
Suor excessivo.
Infecções recorrentes no peito.
In children, severe abdominal pain may indicate coronary insufficiency.
Sinais
Onset may be acute and result in choque cardiogênico or sudden death.7
Respiratory distress during feeding - tachypnoea, grunting, subcostal or intercostal recession.
Febre.
Pallor (anaemia).
Peripheral cyanosis.
Cardiomegaly - normal or quiet first and second heart sounds, a gallop rhythm with an audible third heart sound.
Apical pansystolic murmur.
Hepatomegalia.
Edema.
Erupção cutânea.
Leukocytosis.
There is also an increased risk of thromboembolic episodes.
It may present as part of Barth's syndrome, which comprises cardiomiopatia dilatada ± endocardial fibroelastosis.8
Investigações
Voltar ao conteúdoExames de sangue:
Blood urea and creatinine.
Hemograma completo.
Autoantibody profile (including anti-Ro and anti-La).9
Blood culture tests indicated for management of acute episodes.
CXR:
Cardiothoracic (CT) ratio exceeds 0.65.
Left lower lobe atelectasis may be seen.
The cardiac silhouette is often globular.
Pulmonary venous congestion is common.
ECG:
Tall R waves.
Deep Q waves.
T-wave inversion or flattening in the left precordial or inferior lead.
Findings depict left ventricular (LV) hypertrophy.
Right axis deviation and isolated right ventricular (RV) hypertrophy (more common in the first few weeks of life).
Left, right (or both) atrial enlargement.
Síndrome de Wolff-Parkinson-White, left bundle branch block, supraventricular and ventricular arrhythmias and varying degrees of atrioventricular block.
The early and terminal stages of heart failure show low-voltage tracings.
Echocardiography:
Increase in left atrium and LV dimensions.
Reduced ejection fraction.
Abnormal mitral valve motion.
Dense echogenicity along the endocardium of the LV.
A varying degree of regurgitação mitral is common.
Fetal echocardiography:
Although an echocardiogram is commonly performed, research has shown that cardiac magnetic resonance (CMR) might be more visual and accurate in evaluating morphological and functional cardiac changes.6
Endocardial fibroelastosis treatment and management
Voltar ao conteúdoThe management is as per the manejo da insuficiência cardíaca. In severe cases, surgical management with left ventricular decortication may be required.12
Cardiac transplantation may be recommended.
Prognóstico
Voltar ao conteúdoThe prognosis for primary endocardial fibroelastosis is relatively poor:13
The 4-year survival rate is 77%.
It is worse in infants who present with acutely decompensated heart failure and they are less likely to survive unless they receive a transplant.
Surviving patients often experience persistent symptoms.
An ECG 'infarct' pattern in a child with endocardial fibroelastosis is usually associated with death and is a negative prognostic sign for survival.
The prognosis for secondary endocardial fibroelastosis is variable, depending on the underlying disease process and severity.
Leitura adicional e referências
- Weixler V, Marx GR, Hammer PE, et al; Flow disturbances and the development of endocardial fibroelastosis. J Thorac Cardiovasc Surg. 2020 Feb;159(2):637-646. doi: 10.1016/j.jtcvs.2019.08.101. Epub 2019 Sep 26.
- Xu X, Friehs I, Zhong Hu T, et al; Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. Circ Res. 2015 Feb 27;116(5):857-66. doi: 10.1161/CIRCRESAHA.116.305629. Epub 2015 Jan 13.
- Lurie PR; Changing concepts of endocardial fibroelastosis. Cardiol Young. 2010 Apr;20(2):115-23. Epub 2010 Mar 29.
- Endocardial Fibroelastosis; Herança Mendeliana Online no Homem (OMIM)
- Rodriguez MM, Bruce JH, Jimenez XF, et al; Nonimmune hydrops fetalis in the liveborn: series of 32 autopsies. Pediatr Dev Pathol. 2005 May-Jun;8(3):369-78. Epub 2005 Jul 14.
- Xiao W, Wang Y, Cheng W, et al; The value of cardiac magnetic resonance imaging in endocardial fibroelastosis. Front Pediatr. 2022 Nov 1;10:874597. doi: 10.3389/fped.2022.874597. eCollection 2022.
- Valdes-Dapena M, Gilbert-Barness E; Cardiovascular causes for sudden infant death. Pediatr Pathol Mol Med. 2002 Mar-Apr;21(2):195-211.
- Steward CG, Newbury-Ecob RA, Hastings R, et al; Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth. Prenat Diagn. 2010 Oct;30(10):970-6.
- Buyon JP, Rupel A, Clancy RM; Neonatal lupus syndromes. Lupus. 2004;13(9):705-12.
- Weiner Z, Shalev E; Doppler fetal echocardiography in endocardial fibroelastosis. Obstet Gynecol. 2001 Nov;98(5 Pt 2):933-5.
- Clur SA, van der Wal AC, Ottenkamp J, et al; Echocardiographic evaluation of fetal cardiac function: clinical and anatomical Fetal Diagn Ther. 2010;28(1):51-7. Epub 2010 Apr 16.
- Chan JL, Rosing DR, Klion AD, et al; Surgical management of adult endocardial fibroelastosis. J Thorac Cardiovasc Surg. 2017 Nov;154(5):e81-e84. doi: 10.1016/j.jtcvs.2017.05.050. Epub 2017 May 23.
- Sana MK, Mahajan K; Endocardial Fibroelastosis. StatPearls, Jan 2023.
Continue lendo abaixo
About the author

Dr Colin Tidy, MRCGP
Médico Generalista, Autor Médico
MBBS, MRCGP, MRCP (Paediatrics), DCH
Dr Colin Tidy é um médico do NHS, baseado em Oxfordshire.
About the reviewerView full bio

Dr Krishna Vakharia, MRCGP
Chief Medical Officer for Health, Optum UK
MBChB, MRCGP(2013), BMedSci (hons), DFSRH, DRCOG, PGDipDerm (Distn)
Dr. Krishna Vakharia é uma médica de clínica geral do NHS. Ela também é examinadora regular do Diploma de Pós-Graduação em Dermatologia Prática na Universidade de Cardiff, além de ser a Diretora Médica de Saúde na Optum UK.
Histórico do artigo
As informações nesta página são escritas e revisadas por clínicos qualificados.
Próxima revisão prevista: 17 Ago 2028
21 Set 2023 | Última versão

Pergunte, compartilhe, conecte-se.
Navegue por discussões, faça perguntas e compartilhe experiências em centenas de tópicos de saúde.

Sentindo-se mal?
Avalie seus sintomas online gratuitamente